TRV
SAGE

Third Rock Ventures’s Sage Therapeutics SAGE Stock Holding History

Third Rock Ventures’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$273M Sell
6,442,916
-2,330,157
-27% -$144M 25.46% 2
2015
Q2 		$640M Sell
8,773,073
-1,000,000
-10% -$64.3M 66.66% 1
2015
Q1 		$491M Sell
9,773,073
-1,907,935
-16% -$82M 52.36% 1
2014
Q4 		$428M Hold
11,681,008
– – 34.97% 1
2014
Q3 		$368M Buy
+11,681,008
New +$338M 42.92% 1

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Third Rock Ventures's SAGE Position: Q3 2015 in Review

Third Rock Ventures reduced its Sage Therapeutics (SAGE) stake by 27% in Q3 2015, selling an estimated $144M and leaving 6,442,916 shares worth $273M. The position accounts for 25.46% of the portfolio, ranked #2.

Third Rock Ventures first reported a position in SAGE in Q3 2014 and has held it in 5 quarters since. The position peaked at $640M in Q2 2015. 134 funds tracked by Wall St. Rank hold SAGE as of Q3 2015.

  • Third Rock Ventures held 6,442,916 shares of Sage Therapeutics worth $273M as of Q3 2015.
  • Third Rock Ventures sold 2,330,157 Sage Therapeutics shares in Q3 2015, an estimated $144M.
  • Sage Therapeutics made up 25.46% of Third Rock Ventures's portfolio in Q3 2015, its #2 holding.
  • Third Rock Ventures first reported a position in Sage Therapeutics in Q3 2014 and has held it in 5 quarters since.
  • Third Rock Ventures's Sage Therapeutics position peaked at $640M in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2015.

Based on Third Rock Ventures's 13F filing for Q3 2015, filed 3 Nov 2015.